Digital health technologies (DHTs) are becoming more prevalent in clinical investigations and having the correct knowledge on how to utilize these technologies is essential if you choose to implement them. On December 21, 2023, FDA released the final guidance...
In the realm of medical devices, the European Union’s Medical Devices Regulation (MDR) stands as a cornerstone, ensuring that devices are rigorously evaluated for safety and effectiveness. The recent update to the Medical Device Coordination Group’s (MDCG) guidance -...
Introduction “Process to Request a Review of FDA’s Decision Not to Issue Certain Export Certificates for Devices” outlined in this document navigates the regulatory landscape established by the FDA Reauthorization Act of 2017 (FDARA), particularly Section 704, and the...
Introduction The MITRE Corporation created the White Paper "Next Steps Toward Managing Legacy Medical Device Cybersecurity Risks" in November 2023. While not official FDA guidance, it gathers insights from industry stakeholders, the FDA, and other government...
Introduction On November 7, 2023, FDA formally recognized a new cybersecurity standard titled ANSI AAMI SW96:2023 Standard for medical device security – Security risk management for device manufacturers [1]. This announcement comes after the standard was added to...
On October 24th, 2023, U.S. Food and Drug Administration (FDA), Health Canada, and U.K Medicines and Healthcare products Regulatory Agency (MHRA) published 5 guidance principles for predetermined change control plans (PCCPs). These principles are designed to guide the...
Introduction On September 29th, FDA announced a proposed rule regarding Laboratory Developed Tests (LDTs). LDTs are IVDs that are designed, developed, and used within a single laboratory. This new rule aims to improve the safety and effectiveness of these tests by...
Introduction to the Guidance FDA issued a new guidance document “Antimicrobial Susceptibility Test (AST) System Devices – Updating Breakpoints in Device Labeling”. The purpose of this guidance document, issued on September 29, 2023, is to inform industry of the...
While the FDA has issued extensive guidance to outline premarket submission requirements and relevant acceptance criteria, manufacturer discretion in the implementation of these requirements often results in a lack of uniformity in the way submissions are prepared and...
On September 15th, 2023, the FDA issued an updated final guidance on the Breakthrough Devices Program. As established by section 515B of the Federal Food, Drug, and Cosmetic Act, the Breakthrough Devices Program is intended to expedite the development and review of...